

Multiple Myeloma Treatment Pathways**

Patient Name: _____ **Date of Birth:** _____

Member ID: _____ **Treatment Start Date:** _____

Stage: _____ **Pathology:** _____

ECOG Status: 1 2 3 4 **ICD-10 Code:** _____

Line of Therapy:
 1st Line 2nd Line 3rd Line 3rd Line+ Maintenance

Biomarkers/Attributes: (select all that apply)

Transplant Candidate: <input type="checkbox"/> Yes <input type="checkbox"/> No	T (11;14) Translocations: <input type="checkbox"/> Present <input type="checkbox"/> Absent <input type="checkbox"/> Not reported
Prior Transplant: <input type="checkbox"/> Yes <input type="checkbox"/> No	

Primary Therapy | Transplant Eligible

- Bortezomib + lenalidomide + dexamethasone (VRD)
- Bortezomib + thalidomide + dexamethasone (VTD)
- Bortezomib + cyclophosphamide + dexamethasone (CyBorD or VCD)

Primary Therapy | Transplant Ineligible

- Bortezomib + lenalidomide + dexamethasone (VRD)
- Bortezomib + cyclophosphamide + dexamethasone (CyBorD or VCD)

Maintenance Therapy | Transplant Eligible & Ineligible

- Lenalidomide
- Bortezomib

Relapsed or Refractory | 1st Relapse

- Daratumumab + lenalidomide + dexamethasone (DRD)
- Daratumumab + bortezomib + dexamethasone (DVD)
- Isatuximab-irfc + pomalidomide + dexamethasone (Isa-PD)
- Bortezomib + lenalidomide + dexamethasone (VRD)
- Bortezomib + cyclophosphamide + dexamethasone (CyBorD or VCD)

Relapsed or Refractory | 2nd Relapse

- Daratumumab + lenalidomide + dexamethasone (DRD)
- Daratumumab + bortezomib + dexamethasone (DVD)
- Isatuximab-irfc + pomalidomide + dexamethasone (Isa-PD)
- Elotuzumab + pomalidomide + dexamethasone (EPD)
- Carfilzomib + lenalidomide + dexamethasone (KRD)
- Pomalidomide + bortezomib + dexamethasone (PVD)
- Bortezomib + lenalidomide + dexamethasone (VRD)
- Bortezomib + cyclophosphamide + dexamethasone (CyBorD or VCD)

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.



**Therapies that are administered at Centers of Excellence, including stem cell transplant or CAR T-cell therapy, are not included in pathways. Patients eligible for transplant or CAR T-cell therapy should be referred appropriately for evaluation.

References:

- Attal, M., Lauwers-Cances, V., Marit, G., et al. Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma. *N Engl J Med*. 2012;366(19):1782-1791. doi:10.1056/NEJMoa1114138
- Attal, M., Richardson, P.G., Rajkumar, S.V., et al., ICARIA-MM Study Group. Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study. *Lancet*. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140- 6736(19)32556-5. Epub 2019 Nov 14. Erratum in: *Lancet*. 2019 Dec 7;394(10214):2072. PMID: 31735560.
- Barlogie, B., Anaissie, E., van Rhee, F., et al. Incorporating Bortezomib into Upfront Treatment for Multiple Myeloma: Early Results of Total Therapy. *Br J Haematol*. 2007;138(2):176-185. DOI: 10.1111/j.1365-2141.2007.06639.
- Basali, D., Chakraborty, R., Rybicki, L., et al. Real-World Data on Safety and Efficacy of VenetoclaxBased Regimens in Relapsed/Refractory T(11;14) Multiple Myeloma. *Br J Haematol*. 2020 Jun;189(6):1136-1140. doi: 10.1111/bjh.16454. Epub 2020 Feb 3. PMID: 32012228.
- Baz, R.C., Martin, T.G., Lin, H.Y., et al. Randomized Multicenter Phase 2 Study of Pomalidomide, Cyclophosphamide, and Dexamethasone in Relapsed Refractory Myeloma. *Blood*. 2016;127:2561- 2568. Retrieved from ncbi.nlm.nih.gov/pubmed/26932802.
- Benboubker, L., Dimopoulos, M.A., Dispenzieri, A., et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients With Myeloma. *N Engl J Med*. 2014;371:906–917.
- Berdeja, J.G., Hart, L.L., Mace, J.R., et al. Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma. *Haematologica*. 2015 May;100(5):670-6. doi: 10.3324/haematol.2014.119735. Epub 2015 Feb 20. PMID: 25710456; PMCID: PMC4420216.
- Bringhen, S., Petrucci, M.T., Larocca, A., et al. Carfilzomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: A Multicenter, Phase 2 Study. *Blood*. 2014;124(1):63-69. doi:10.1182/blood-2014-03-563759
- Buda, G., Orciuolo, E., Galimberti, S., et al. VDTSPACE as Salvage Therapy for Heavily Pretreated MM Patients. *Blood*. 2013; 122 (21): 5377. Retrieved from doi.org/10.1182/blood.V122.21.5377.5377
- Cavo, M., Rajkumar, S.V., Palumbo, A., et al. International Myeloma Working Group. International Myeloma Working Group Consensus Approach to the Treatment of Multiple Myeloma Patients Who Are Candidates for Autologous Stem Cell Transplantation. *Blood*. 2011 Jun 9;117(23):6063-73. doi: 10.1182/blood-2011-02-297325. Epub 2011 Mar 29. PMID: 21447828; PMCID: PMC3293742.
- Cavo, M., Tacchetti, P., Patriarca, F., et al. Bortezomib With Thalidomide Plus Dexamethasone Compared With Thalidomide Plus Dexamethasone as Induction Therapy Before, and Consolidation Therapy After, Double Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Randomised Phase 3 Study [Published Correction Appears in *Lancet*. 2011 Nov 26;378(9806):1846]. *Lancet*. 2010;376(9758):2075-2085. DOI: 10.1016/S0140-6736(10)61424-9 PCA-1-20-04075-Clinical-QRG_01042021 78
- Chari, A., Cho, H.J., Dhadwal, A., et al. A Phase 2 Study of Panobinostat With Lenalidomide and Weekly Dexamethasone in Myeloma. *Blood Adv*. 2017 Aug 21;1(19):1575-1583. doi: 10.1182/bloodadvances.2017007427. PMID: 29296798; PMCID: PMC5728465. PCA-1-20-04075-Clinical-QRG_01042021 86
- Chari, A., Martinez-Lopez, J., Mateos, M.V., et al. Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. *Blood*. 2019 Aug 1;134(5):421-431. Doi: 10.1182/blood.2019000722. Epub 2019 May 21. PMID: 31113777; PMCID: PMC6676132.
- Chari, A., Suvannasankha, A., Fay, J.W., et al. Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. *Blood*. 2017;130:974-981. Retrieved from ncbi.nlm.nih.gov/pubmed/28637662.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Chari, A., Vogl, D.T., Gavriatopoulou, M., et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. *N Engl J Med.* 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. PMID: 31433920.

Davies, F.E., Wu, P., Jenner, M., Srikanth, M., Saso, R., Morgan, G.J. The Combination of Cyclophosphamide, Velcade and Dexamethasone Induces High Response Rates with Comparable Toxicity to Velcade Alone and Velcade Plus Dexamethasone. *Haematologica.* 2007 Aug;92(8):1149-50. doi: 10.3324/haematol.11228. PMID: 17650451.

Dimopoulos, M., Quach, H., Mateos, M.V., et al. Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CANDOR): Results from a Randomised, Multicentre, Open-Label, Phase 3 Study. *Lancet.* 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0. Erratum in: *Lancet.* 2020 Aug 15;396(10249):466. PMID: 32682484.

Dimopoulos, M.A., Dytfeld, D., Grosicki, S., et al. Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma. *N Engl J Med.* 2018;379:1811-1822. Retrieved from ncbi.nlm.nih.gov/pubmed/30403938.

Dimopoulos, M.A., Gay, F., Schjesvold, F., et al. Oral Ixazomib Maintenance Following Autologous Stem Cell Transplantation (TOURMALINE-MM3): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial. *Lancet.* 2019;393(10168):253-264. DOI: 10.1016/S0140-6736(18)33003-4

Dimopoulos, M.A., Goldschmidt, H., Niesvizky, R., et al. Carfilzomib or Bortezomib in Relapsed or Refractory Multiple Myeloma (ENDEAVOR): An Interim Overall Survival Analysis of an Open Label, Randomised, Phase 3 Trial. *Lancet Oncol.* 2017;18:1327-1337. Retrieved from ncbi.nlm.nih.gov/pubmed/28843768.

Dimopoulos, M.A., Lonial, S., White, D., et al. Elotuzumab Plus Lenalidomide/Dexamethasone for Relapsed or Refractory Multiple Myeloma: ELOQUENT-2 Follow-Up and Post-Hoc Analyses on Progression-Free Survival and Tumour Growth. *Br J Haematol.* 2017;178:896-905. Retrieved from ncbi.nlm.nih.gov/pubmed/28677826.

Dimopoulos, M.A., Lonial, S., White, D., et al. Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results from the Phase 3 Randomized ELOQUENT-2 Study. *Blood Cancer J.* 2020;10:91. Retrieved from ncbi.nlm.nih.gov/pubmed/32887873. PCA-1-20-04075-Clinical-QRG_01042021 84

Dimopoulos, M.A., Moreau, P., Palumbo, A., et al. Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open Label, Multicentre Study. *Lancet Oncol.* 2016;17:27-38. Retrieved from ncbi.nlm.nih.gov/pubmed/26671818.

Dimopoulos, M.A., Oriol, A., Nahi, H., et al. POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med.* 2016 Oct 6;375(14):1319-1331. doi:10.1056/NEJMoa1607751. PMID: 27705267.

Dimopoulos, M.A., Palumbo, A., Corradini, P., Cavo, M., Delforge, M., Di Raimondo F., et al. Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone in STRATUS (MM-010): A Phase 3b Study in Refractory Multiple Myeloma. *Blood.* 2016;128:497-503

Durie, B.G.M., Hoering, A., Abidi, M.H., et al. Bortezomib With Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Patients with Newly Diagnosed Myeloma Without

Einsele, H., Engelhardt, M., Tappich, C., et al; Phase II Study of Bortezomib, Cyclophosphamide and Dexamethasone as Induction Therapy in Multiple Myeloma: DSMM XI Trial. *Br J Haematol.* 2017 Nov;179(4):586-597. doi: 10.1111/bjh.14920. Epub 2017 Sep 29. PMID: 28961309.

Facon, T., Kumar, S., Plesner, T., et al. Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma. *N Engl J Med.* 2019 May 30;380(22):2104-2115. PMID: 31141632

Garderet, L., Kuhnowski, F., Berge, B., et al. Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed Multiple Myeloma. *Blood.* 2018; 132 (24): 2555-2563. Retrieved from doi.org/10.1182/blood-2018-07-863829.

Gay, F., Hayman, S.R., Lacy, M.Q., et al. Lenalidomide Plus Dexamethasone Versus Thalidomide Plus Dexamethasone in Newly Diagnosed Multiple Myeloma: A Comparative Analysis of 411 Patients. *Blood.* 2010; 115:1343-1350. PMID: 20008302.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Giri, S., Grimshaw, A., Bal, S. et al. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-Analysis. *JAMA Oncol.* 2020 Sep 24;6(11):1–8. doi: 10.1001/jamaoncol.2020.4338. Epub ahead of print. PMID: 32970151; PMCID: PMC7516804.

Goldschmidt, H., et al. Bortezomib Before and After High-Dose Therapy in Myeloma: Long-Term Results From the Phase III HOVON-65/GMMG-HD4 Trial. *Leukemia.* 32, 383–390 (2018)

Goldsmith, S., Fiala, M.A., Wang, B.B., et al. Bendamustine in Patients With Quad- and PentaRefractory Multiple Myeloma. *Blood.* 2018; 132 (Supplement 1): 5627. Retrieved from doi.org/10.1182/blood-2018-99-112258.

Holstein, S.A., Jung, S.H., Richardson, P.G., et al; Updated Analysis of CALGB (Alliance) 100104 Assessing Lenalidomide Versus Placebo Maintenance After Single Autologous Stem-Cell Transplantation for Multiple Myeloma: A Randomised, Double-Blind, Phase 3 Trial. *Lancet Haematol.* 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. Erratum in: *Lancet Haematol.* 2018 Aug;5(8):e332. Erratum in: *Lancet Haematol.* 2018 Dec;5(12):e608. PMID: 28826616; PMCID: PMC5718627.

Huang, J., Phillips, S., Byrne, M. et al. Lenalidomide vs. Bortezomib Maintenance Choice PostAutologous Hematopoietic Cell Transplantation for Multiple Myeloma. *Bone Marrow Transplant* 53, 701–707 (2018). Retrieved from doi.org/10.1038/s41409-018-0177-6.

Intent for Immediate Autologous Stem-Cell Transplant (SWOG S0777): A Randomised, Open-Label, Phase 3 Trial. *Lancet.* 2017;389(10068):519-527. DOI: 10.1016/S0140-6736(16)31594-X

Isoda, A., Murayama, K., Ito, S., et al. Kanshinetsu Multiple Myeloma Study Group. Bortezomib Maintenance Therapy in Transplant-Ineligible Myeloma Patients Who Plateaued After Bortezomib Based Induction Therapy: A Multicenter Phase II Clinical Trial. *Int J Hematol.* 2018 Jul;108(1):39-46. doi: 10.1007/s12185-018-2448-9. Epub 2018 Mar 28. PMID: 29594921.

Jackson, G.H., Davies, F.E., Pawlyn, C., et al. UK NCRI Haemato-Oncology Clinical Studies Group. Lenalidomide Maintenance Versus Observation for Patients With Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial. *Lancet Oncol.* 2019 Jan;20(1):57-73. doi: 10.1016/S1470-2045(18)30687-9. Epub 2018 Dec 14. PMID: 30559051; PMCID: PMC6318225.

Jackson, H.G., Davies, F.E., Pawlyn, C., et al. Lenalidomide Maintenance Versus Observation for Patients With Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial. *Lancet Oncol.* 2019;20(1):57-73.

Jakubowiak, A., Offidani, M., Pegourie, B., et al. Randomized Phase 2 Study: Elotuzumab Plus Bortezomib/Dexamethasone Vs. Bortezomib/Dexamethasone for Relapsed/Refractory MM. *Blood.* 2016;127:2833-2840. Retrieved from ncbi.nlm.nih.gov/pubmed/27091875.

Jakubowiak, A.J., Dytfeld, D., Griffith, K.A., et al. A Phase 1/2 Study of Carfilzomib in Combination With Lenalidomide and Low-Dose Dexamethasone as a Frontline Treatment for Multiple Myeloma. *Blood.* 2012;120(9):1801-1809. DOI: 10.1182/blood-2012-04-422683

Jakubowiak, A.J., Dytfeld, D., Griffith, K.A., et al. A Phase 1/2 Study of Carfilzomib in Combination With Lenalidomide and Low-Dose Dexamethasone as a Frontline Treatment for Multiple Myeloma. *Blood.* 2012;120:1801–1809.

Jasielec, J., Kubicki, T., Raje, N., et al. Carfilzomib, Lenalidomide, and Dexamethasone Plus Transplant in Newly Diagnosed Multiple Myeloma. *Blood.* 2020 Jul 31. *Blood.*2020007522. doi: 10.1182/blood.2020007522. Epub ahead of print. PMID: 32735641.

Kaufman, J.L., Mina, R., Jakubowiak, A.J., et al. Combining Carfilzomib And Panobinostat to Treat Relapsed/Refractory Multiple Myeloma: Results of a Multiple Myeloma Research Consortium Phase I Study. *Blood Cancer J.* 2019 Jan 4;9(1):3. doi: 10.1038/s41408-018-0154-8. PMID: 30610196; PMCID: PMC6320362.

Kaufman, J.L., Usmani, S.Z., San-Miguel, J., et al. Four-Year Follow-Up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). *Blood.* 2019; 134 (Supplement_1): 1866. Retrieved from doi.org/10.1182/blood-2019-123483. PCA-1-20-04075-Clinical-QRG_01042021 82

Knop, S., Liebisch, P., Wandt, H., et al. Bortezomib, IV Cyclophosphamide, and Dexamethasone (Velcd) as Induction Therapy in Newly Diagnosed Multiple Myeloma: Results of an Interim Analysis of the German DSMM Trial. *Blood.* 2009;27:8516-8516. Retrieved from doi.org/10.1182/blood.V112.11.2776.2776.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Korde, N., Roschewski, M., Zingone, A., et al. Treatment with Carfilzomib-Lenalidomide Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. *JAMA Oncol.* 2015;1(6):746-754. doi: 10.1001/jamaoncol.2015.2010 PCA-1-20-04075-Clinical-QRG_01042021 77

Korde, N., Zingone, A., Kwok, M., et al. Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients [Abstracts]. *Blood.* 2013;122:538. Retrieved from doi.org/10.1182/blood.V122.21.538.538.

Krishnan, A., Kapoor, P., Palmer, J.M., et al. Phase I/II Trial of the Oral Regimen Ixazomib, Pomalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. *Leukemia.* 2018 Jul;32(7):1567-1574. doi: 10.1038/s41375-018-0038-8. Epub 2018 Feb 23. PMID: 32082000; PMCID: PMC6005710.

Kropff, M., Bisping, G., Schuck, E., et al., Deutsche Studiengruppe Multiples Myelom. Bortezomib in Combination With Intermediate-Dose Dexamethasone and Continuous Low-Dose Oral PCA-1-20-04075-Clinical-QRG_01042021 83 Cyclophosphamide for Relapsed Multiple Myeloma. *Br J Haematol.* 2007 Aug;138(3):330-7. doi:10.1111/j.1365-2141.2007.06656.x. PMID: 17614819.

Kumar, S., Flinn, I., Richardson, P.G., et al. Randomized, Multicenter, Phase 2 Study (EVOLUTION) of Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Previously Untreated Multiple Myeloma. *Blood.* 2012;119(19):4375-4382. DOI: 10.1182/blood-2011-11-395749

Kumar, S., Kaufman, J.L., Gasparetto, C., et al. Efficacy of Venetoclax as Targeted Therapy for Relapsed/Refractory T(11;14) Multiple Myeloma. *Blood.* 2017; 130 (22): 2401–2409. Retrieved from doi.org/10.1182/blood-2017-06-788786

Kumar, S.K., Berdeja, J.G., Niesvizky, R., et al. Ixazomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Long-Term Follow-Up Including Ixazomib Maintenance. *Leukemia.* 2019;33(7):1736-1746. doi:10.1038/s41375-019-0384-1

Kumar, S.K., Berdeja, J.G., Niesvizky, R., et al. Safety and Tolerability of Ixazomib, an Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients With Previously Untreated Multiple Myeloma: An Open-Label Phase 1/2 Study [published correction appears in *Lancet Oncol.* 2019 Jul;20(7):e346]. *Lancet Oncol.* 2014;15(13):1503-1512. DOI: 10.1016/S1470-2045(14)71125-8

Kumar, S.K., Berdeja, J.G., Niesvizky, R., et al. Safety and Tolerability of Ixazomib, an Oral Proteasome Inhibitor, in Combination With Lenalidomide and Dexamethasone in Patients With Previously Untreated Multiple Myeloma: An Open-Label Phase 1/2 Study. *Lancet Oncol.* 2014;15:1503–1512.

Kumar, S.K., et al. Phase 1/2 Trial Of Ixazomib, Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma. *Blood Cancer Journal.* 2018 Jul 30;8(8):70. DOI: 10.1038/s41408-018-0106-3.

Kumar, S.K., Grzasko, N., Delimpasi, S., et al. Phase 2 Study of All-Oral Ixazomib, Cyclophosphamide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma. *Br J Haematol.* 2019;184:536-546. Retrieved from ncbi.nlm.nih.gov/pubmed/30460684.

Kumar, S.K., Jacobus, S.J., Cohen, A.D., et al. Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma Without Intention for Immediate Autologous Stem-Cell Transplantation (ENDURANCE): A Multicentre, OpenLabel, Phase 3, Randomised, Controlled Trial. *Lancet Oncol.* 2020 Aug 28:S1470-2045(20)30452-6. doi: 10.1016/S1470-2045(20)30452-6. Epub ahead of print. PMID: 32866432.

Kumar, S.K., Lacy, M.Q., Hayman, S.R., et al. Lenalidomide, Cyclophosphamide and Dexamethasone (Crd) for Newly Diagnosed Multiple Myeloma: Results From a Phase 2 Trial. *Am J Hematol.* 2011;86(8):640-645. DOI: 10.1002/ajh.22053

Kumar, S.K., Lacy, M.Q., Hayman, S.R., et al. Lenalidomide, Cyclophosphamide and Dexamethasone (Crd) for Newly Diagnosed Multiple Myeloma: Results From a Phase 2 Trial. *Am J Hematol.* 2011 Aug;86(8):640-5. doi: 10.1002/ajh.22053. Epub 2011 May 31. PMID: 21630308; PMCID: PMC3901994.

Kumar, S.K., LaPlant, B., Roy, V., et al. Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib. *Blood Cancer J.* 2015 Aug 14;5(8):e338. doi: 10.1038/bcj.2015.60. PMID: 26275080; PMCID: PMC4558585.

Kumar, S.K., Laplant, B.R., Reeder, C.B., et al. Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib. *Blood.* 2015; 126 (23): 3050. Retrieved from doi.org/10.1182/blood.V126.23.3050.3050.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Lakshman, A., Singh, P.P., Rajkumar, S.V., et al. Efficacy of VDT PACE-Like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma. *Am J Hematol.* 2018 Feb;93(2):179-186. doi: 10.1002/ajh.24954. Epub 2017 Nov 10. PMID: 29067723.

Lee, C.K., Barlogie, B., Munshi, N., et al. DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma. *J Clin Oncol.* 2003 Jul15;21(14):2732-9. doi: 10.1200/JCO.2003.01.055. Erratum in: *J Clin Oncol.* 2008 Apr 20;26(12): 2066. PMID: 12860952.

Lentzsch, S., O'Sullivan, A., Kennedy, R.C., et al. Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients With Relapsed or Refractory Multiple Myeloma Is Feasible and Highly Effective: Results of Phase 1/2 Open-Label, Dose Escalation Study. *Blood.* 2012 May 17;119(20):4608-13. doi: 10.1182/blood-2011-12-395715. Epub 2012 Mar 26. PMID: 22451423; PMCID: PMC3392072.

Lonial, S., Dimopoulos, M., Palumbo, A., et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. *N Engl J Med.* 2015;373:621- 631. Retrieved from ncbi.nlm.nih.gov/pubmed/26035255.

Lonial, S., Lee, H.C., Badros, A., et al. Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study. *Lancet Oncol.* 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16. PMID: 31859245.

Mateos, M.V., Dimopoulos, M.A., Cavo, M., et al; ALCYONE Trial Investigators. Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. *N Engl J Med.* 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. PMID: 29231133.

Mateos, M.V., Sonneveld, P., Hungria, V., et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: ThreeYear Follow-up of CASTOR. *Clin Lymphoma Myeloma Leuk.* 2020 Aug;20(8):509-518. doi: 10.1016/j.clml.2019.09.623. Epub 2019 Oct 9. PMID: 32482541.

McCarthy, P.L. et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. *J. Clin. Oncol.* 35, 3279–3289 (2017).

McCarthy, P.L., Owzar, K., Hofmeister, C.C., et al. Lenalidomide After Stem-Cell Transplantation for Multiple Myeloma. *N Engl J Med.* 2012;366(19):1770-1781. doi:10.1056/NEJMoa1114083

Mikhael, J., Ismaila, N., Cheung, M.C., et al. ASCO and CCO Joint Clinical Practice Guideline. *J Clin Oncol.* 2019 May 10;37(14):1228-1263. doi: 10.1200/JCO.18.02096. Epub 2019 Apr 1. Erratum in: *J Clin Oncol.* 2020 Jul 20;38(21):2469. PMID: 30932732.

Mikhael, J.R., Belch, A.R., Prince, H.M., et al. High Response Rate to Bortezomib With or Without Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Results of a Global Phase 3b Expanded Access Program. *Br J Haematol.* 2009 Jan;144(2):169-75. doi: 10.1111/j.1365-2141.2008.07409.x. Epub 2008 Nov 19. PMID: 19036114

Mikhael, J.R., Reeder, C.B., Libby, E.N., et al. Phase Ib/II Trial of CYKLONE (Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone) for Newly Diagnosed Myeloma. *Br J Haematol.* 2015 Apr;169(2):219-27. doi: 10.1111/bjh.13296. Epub 2015 Feb 13. PMID: 25683772; PMCID: PMC4521972.

Mina, R., Bonello, F., Petrucci, M.T., et al. Carfilzomib, Cyclophosphamide and Dexamethasone for Newly Diagnosed, High-Risk Myeloma Patients Not Eligible for Transplant: A Pooled Analysis of Two Studies. *Haematologica.* 2020;105(4):243428. DOI: 3324/haematol.2019.243428

Moreau, P., Attal, M., Hulin, C., et al. Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study. *Lancet.* 2019;394(10192):29-38. DOI: 10.1016/S0140-6736(19)31240-1

Moreau, P., Avet-Loiseau, H., Facon, T., et al. Bortezomib Plus Dexamethasone Versus Reduced-Dose Bortezomib, Thalidomide Plus Dexamethasone as Induction Treatment Before Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. *Blood.* 2011;118(22):5752-5982. DOI: 10.1182/blood-2011-05-355081

Moreau, P., Hulin, C., Macro, M., et al. VTD Is Superior to VCD Prior to Intensive Therapy in Multiple Myeloma: Results of the Prospective IFM2013-04 Trial. *Blood.* 2016;127(21):2569-2574. DOI: 10.1182/blood-2016-01-693580

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Moreau, P., Masszi, T., Grzasko, N., et al; TOURMALINE-MM1 Study Group. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med.* 2016 Apr 28;374(17):1621-34. Doi: 10.1056/NEJMoa1516282. PMID: 27119237

Morgan, G.J., Schey, S.A., Wu, P., et al. Lenalidomide (Revlimid), in Combination With Cyclophosphamide and Dexamethasone (RCD), Is an Effective and Tolerated Regimen for Myeloma Patients. *Br J Haematol.* 2007;137:268-269. Retrieved from ncbi.nlm.nih.gov/pubmed/17408469.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Accessed Nov. 2, 2020.

Niesvizky, R., Flinn, I.W., Rifkin, R., et al. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. *J Clin Oncol.* 2015;33(33):3921-3929. DOI: 10.1200/JCO.2014.58.7618

Niesvizky, R., Flinn, I.W., Rifkin, R., et al. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. *J Clin Oncol.* 2015 Nov 20;33(33):3921-3929. PMID: 26056177

Offidani, M., Corvatta, L., Maracci, L., et al. Efficacy and Tolerability of Bendamustine, Bortezomib and Dexamethasone in Patients With Relapsed-Refractory Multiple Myeloma: A Phase II Study. *Blood Cancer J.* 2013 Nov 22;3(11):e162. Doi: 10.1038/bcj.2013.58. PMID: 24270324; PMCID: PMC3880441.

Orlowski, R.Z., Moreau, P., Niesvizky, R., et al. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. *Clin Lymphoma Myeloma Leuk.* 2019 Aug;19(8):522-530.e1. doi: 10.1016/j.clml.2019.04.018. Epub 2019 May 2. PMID: 31160237.

Orlowski, R.Z., Nagler, A., Sonneveld, P., et al. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression. *J Clin Oncol.* 2007 Sep 1;25(25):3892-901. doi: 10.1200/JCO.2006.10.5460. Epub 2007 Aug 6. PMID: 17679727.

Palumbo, A., Cavallo, F., Gay, F., et al. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. *N Engl J Med.* 2014;371(10):895-905. doi:10.1056/NEJMoa1402888 PCA-1-20-04075-Clinical-QRG_01042021 79

Palumbo, A., Cavallo, F., Gay, F., et al. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. *N Engl J Med.* 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888. PMID: 25184862.

Palumbo, A., Chanan-Khan, A., Weisel, K., et al. CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. *N Engl J Med.* 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. PMID: 27557302.

Palumbo, A., Hajek, R., Delforge, M., et al. MM-015 Investigators. Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. *N Engl J Med.* 2012 May 10;366(19):1759-69. doi:10.1056/NEJMoa1112704. Erratum in: *N Engl J Med.* 2012 Jul 19;367(3):285.

Palumbo, A., Sezer, O., Kyle, R., et al. IMWG. International Myeloma Working Group Guidelines for the Management of Multiple Myeloma Patients Ineligible for Standard High-Dose Chemotherapy With Autologous Stem Cell Transplantation. *Leukemia.* 2009 Oct;23(10):1716-30. doi: 10.1038/leu.2009.122. Epub 2009 Jun 4. PMID: 19494840. PCA-1-20-04075-Clinical-QRG_01042021 81

Park, S., Lee, S.J., Jung, C.W., et al. DCEP for Relapsed or Refractory Multiple Myeloma After Therapy With Novel Agents. *Ann Hematol.* 2014 Jan;93(1):99-105. doi: 10.1007/s00277-013-1952-5. Epub 2013 Nov 16. PMID: 24240976.

PCA-1-20-04075-Clinical-QRG_01042021 85

Rajkumar, S.V., Jacobus, S., Callander, N.S., et al. Eastern Cooperative Oncology Group. Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma: An Open-Label Randomised Controlled Trial. *Lancet Oncol.* 2010 Jan;11(1):29-37. doi: 10.1016/S1470-2045(09)70284-0. Epub 2009 Oct 21. Erratum in: *Lancet Oncol.* 2010 Jan;11(1):14. PMID: 19853510; PMCID: PMC3042271.

Reeder, C.B., Reece, D.E., Kukreti, V., et al. Cyclophosphamide, Bortezomib and Dexamethasone Induction for Newly Diagnosed Multiple Myeloma: High Response Rates in a Phase II Clinical Trial. *Leukemia.* 2009;23(7):1337-1341. DOI: 10.1038/leu.2009.26

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Reeder, C.B., Reece, D.E., Kukreti, V., et al. Long-Term Survival With Cyclophosphamide, Bortezomib and Dexamethasone Induction Therapy in Patients With Newly Diagnosed Multiple Myeloma. *Br J Haematol*. 2014;167(4):563-565. Retrieved from doi.org/10.1111/bjh.13004.

Reeder, C.B., Reece, D.E., Kukreti, V., et al. Once- Versus Twice-Weekly Bortezomib Induction Therapy With Cybord in Newly Diagnosed Multiple Myeloma. *Blood*. 2010;115(16):3416-3417. DOI: 10.1182/blood-2010-02-271676

Richardson, P.G., Oriol, A., Beksac, M., et al., OPTIMISMM trial investigators. Pomalidomide, Bortezomib, and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial. *Lancet Oncol*. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. PMID: 31097405.

Richardson, P.G., Schlossman, R.L., Alsina, M., et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. *Blood*. 2013;122:2331-2337. Retrieved from ncbi.nlm.nih.gov/pubmed/23950178.

Richardson, P.G., Weller, E., Lonial, S., et al. Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma. *Blood*. 2010;116(5):679- 686. doi: 10.1182/blood-2010-02-268862

Richardson, P.G., Xie, W., Jagannath, S., et al. A Phase 2 Trial of Lenalidomide, Bortezomib, and Dexamethasone in Patients With Relapsed and Relapsed/Refractory Myeloma. *Blood*. 2014 Mar 6;123(10):1461-9. doi: 10.1182/blood-2013-07-517276. Epub 2014 Jan 15. PMID: 24429336; PMCID: PMC4123434.

Rosenbaum, C.A., Stephens, L.A., Kukreti, V., et al. Phase 1/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (Kpd) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): A Multiple Myeloma Research Consortium Multicenter Study. *ASCO Meeting Abstracts* 2016;34:8007. Retrieved from meeting.ascopubs.org/cgi/content/abstract/34/15_suppl/8007.

Rosiñol, L., Oriol, A., Teruel, A.I., et al. Superiority of Bortezomib, Thalidomide, and Dexamethasone (VTD) as Induction Pretransplantation Therapy in Multiple Myeloma: A Randomized Phase 3 PETHEMA/GEM Study. *Blood*. 2012;120(8):1589-1596. DOI: 10.1182/blood-2012-02-408922

Roussel, M., Lauwers-Cances, V., Robillard, N., et al. Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination as Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome. *J Clin Oncol*. 2014;32(25):2712-2717. DOI: 10.1200/JCO.2013.54.8164

San Miguel, J., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., et al. Pomalidomide Plus LowDose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial. *Lancet Oncol*. 2013;14:1055–66

San-Miguel, J.F., Hungria, V.T., Yoon, S.S., et al. Overall Survival of Patients With Relapsed Multiple Myeloma Treated With Panobinostat or Placebo Plus Bortezomib and Dexamethasone (The PANORAMA 1 Trial): A Randomised, Placebo-Controlled, Phase 3 Trial. *Lancet Haematol*. 2016 Nov;3(11):e506-e515. doi: 10.1016/S2352-3026(16)30147-8. Epub 2016 Oct 14.

Shah, J.J., Stadtmauer, E.A., Abonour, R., et al. Carfilzomib, Pomalidomide, and Dexamethasone for Relapsed or Refractory Myeloma. *Blood*. 2015;126:2284-2290. Retrieved from ncbi.nlm.nih.gov/pubmed/26384354.

Siegel, D.S., Dimopoulos, M.A., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A., San-Miguel, J., Obreja, M., Blaedel, J., Stewart, A.K. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. *J Clin Oncol*. 2018 Mar 10;36(8):728-734. doi: 10.1200/JCO.2017.76.5032. Epub 2018 Jan 17. PMID: 29341834.

Singh, et al. Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials. *Blood*. 2013;122 (21): 407. Retrieved from doi.org/10.1182/blood.V122.21.407.407.

Sonneveld, P., Broijl, A., Gay, F., et al. Bortezomib, Lenalidomide, and Dexamethasone (Vrd) +/- Daratumumab (DARA) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM); A Multicenter, Randomized, Phase III Study (PERSEUS). *J Clin Oncol*. 2019;37(15 suppl). 17.

Sonneveld, P., Schmidt-Wolf, I.G., van der Holt, B., et al. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial [published correction appears in *J Clin Oncol*. 2012 Oct 10;30(29):3654]. *J Clin Oncol*. 2012;30(24):2946-2955. DOI: 10.1200/JCO.2011.39.6820

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Spencer, A., Lentzsch, S., Weisel, K., et al. Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Analysis of CASTOR. *Haematologica*. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20. PMID: 30237264; PMCID: PMC6269293.

Srikanth, M., Davies, F.E., Wu, P., et al. Survival and Outcome of Blastoid Variant Myeloma Following Treatment With the Novel Thalidomide Containing Regime DT-PACE. *Eur J Haematol*. 2008 Dec;81(6):432-6. doi: 10.1111/j.1600-0609.2008.01131.x. Epub 2008 Aug 6. PMID: 18691254.

Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., et al; ASPIRE Investigators. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. *N Engl J Med*. 2015 Jan 8;372(2):142-52. Doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. PMID: 25482145.

Usmani, S.Z., Nahi, H., Plesner, T., et al. Daratumumab Monotherapy in Patients With Heavily Pretreated Relapsed or Refractory Multiple Myeloma: Final Results From the Phase 2 GEN501 and SIRIUS Trials. *Lancet Haematol*. 2020 Jun;7(6):e447-e455. doi: 10.1016/S2352-3026(20)30081-8. PMID: 32470437.

Voorhees, P.M., Kaufman, J.L., Laubach, J., et al. Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The GRIFFIN Trial. *Blood*. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288. PMID: 32325490; PMCID: PMC7441167.

Yimer, H., Melear, J., Faber, E., et al. Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed and Relapsed Multiple Myeloma: LYRA Study. *Br J Haematol*. 2019;185(3): 492-502.

Yimer, H., Melear, J., Faber, E., et al. Daratumumab, Bortezomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed and Relapsed Multiple Myeloma: LYRA Study. *Br J Haematol*. 2019 May;185(3):492-502. doi: 10.1111/bjh.15806. Epub 2019 Mar 3. PMID: 30828799; PMCID: PMC6593455.

Yong, K., Brown, S., Hinsley, S., et al. Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen. 2015;126:1840. Retrieved from ash.confex.com/ash/2015/webprogram/scheduler/Paper82080.html.

Zepeda, V.H.J., Duggan, P., Neri, P.E., Bahlis, N. Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) Is a Feasible and Active Regimen for Non-Transplant Eligible Multiple Myeloma Patients [Abstract]. *Blood*. 2014;124:5751. PCA-1-20-04075-Clinical-QRG_01042021 80

Zhang, S., Kulkarni, A.A., Xu, B., et al. Bortezomib-Based Consolidation or Maintenance Therapy for Multiple Myeloma: A Meta-Analysis. *Blood Cancer J*. 10, 33 (2020). Retrieved from doi.org/10.1038/s41408-020-0298-1.

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.